Lenalidomide

Lenalidomide is an immunomodulatory agent with an uncertain mechanism of action in CLL. In one trial of 45 patients treated orally with 25 mg daily for 21 days of a 28-day cycle, 47% of patients achieved a remission.32 Treatment was complicated by a "flare reaction" characterized by a transient worsening of disease in the setting of fevers and sweats. This reaction could be prevented or treated by corticosteroids and dose-

CLL i

Indication for treatment

CLL i

Indication for treatment

Good performance status No comorbidities

0 0

Post a comment